Karyopharm Therapeutics Inc. (KPTI): Price and Financial Metrics


Karyopharm Therapeutics Inc. (KPTI)

Today's Latest Price: $15.33 USD

0.25 (1.66%)

Updated Jan 20 6:55pm

Add KPTI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

KPTI Stock Summary

  • KPTI's price/sales ratio is 12.39; that's higher than the P/S ratio of 85.62% of US stocks.
  • As for revenue growth, note that KPTI's revenue has grown 295.95% over the past 12 months; that beats the revenue growth of 97.7% of US companies in our set.
  • Karyopharm Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -18%, greater than the shareholder yield of only 14.31% of stocks in our set.
  • Stocks that are quantitatively similar to KPTI, based on their financial statements, market capitalization, and price volatility, are FBIO, PROF, QUIK, ATNX, and RDUS.
  • Visit KPTI's SEC page to see the company's official filings. To visit the company's web site, go to www.karyopharm.com.

KPTI Stock Price Chart Interactive Chart >

Price chart for KPTI

KPTI Price/Volume Stats

Current price $15.33 52-week high $29.61
Prev. close $15.08 52-week low $13.39
Day low $14.96 Volume 2,257,200
Day high $15.42 Avg. volume 2,538,383
50-day MA $15.77 Dividend yield N/A
200-day MA $17.07 Market Cap 1.13B

Karyopharm Therapeutics Inc. (KPTI) Company Bio


Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts.


KPTI Latest News Stream


Event/Time News Detail
Loading, please wait...

KPTI Latest Social Stream


Loading social stream, please wait...

View Full KPTI Social Stream

Latest KPTI News From Around the Web

Below are the latest news stories about Karyopharm Therapeutics Inc that investors may wish to consider to help them evaluate KPTI as an investment opportunity.

Karyopharm -8% announces preliminary Q4 and FY numbers

Karyopharm Therapeutics ([[KPTI]] -8.0%) expects total Q4 revenues to be between $35M-36M and between $108M-109M for the FY of 2020, including net product sales for XPOVIO.Additionally, company expects net product sales of XPOVIO to be between $20M-20.5M during Q4 and between $76M- -76.5M for the FY 2020.Net sales for Q4 were...

Seeking Alpha | January 11, 2021

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2020 total revenue estimates including net product sales for XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, and provided additional updates on XPOVIO's commercial progress.

Yahoo Finance | January 11, 2021

Karyopharm/Antengene files application for ATG-010 in China for endometrial cancer

Antengene has submitted an Investigational New Drug ((IND)) application for ATG-010 (selinexor, XPOVIO) being co-developed by Karyopharm Therapeutics (KPTI)  to the National Medical Products Administration ((NMPA)) in the treatment of Endometrial Cancer.The Phase 3, double-blind trial ((SIENDO)) aims to evaluate the efficacy of ATG-010 compared to placebo as maintenance therapy in patients with advanced...

Seeking Alpha | January 5, 2021

Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Monday, January 11 at 4:30 p.m. ET, followed by a question and answer breakout session at 4:50 p.m. ET.

Yahoo Finance | January 4, 2021

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that…

PR Newswire | January 4, 2021

Read More 'KPTI' Stories Here

KPTI Price Returns

1-mo -10.40%
3-mo -2.73%
6-mo -14.45%
1-year -10.98%
3-year 49.27%
5-year 119.00%
YTD -0.97%
2020 -19.25%
2019 104.59%
2018 -2.40%
2017 2.13%
2016 -29.06%

Continue Researching KPTI

Want to see what other sources are saying about Karyopharm Therapeutics Inc's financials and stock price? Try the links below:

Karyopharm Therapeutics Inc (KPTI) Stock Price | Nasdaq
Karyopharm Therapeutics Inc (KPTI) Stock Quote, History and News - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9367 seconds.